Meitheal Pharmaceuticals has reported data from a research partnership with Premier Applied Sciences, where prophylactic treatment with anticoagulants offered enhanced clinical outcomes in hospitalised Covid-19 patients.
Anticoagulants are medications that are used for preventing blood clots. According to research, Covid-19 patients are at an increased risk of developing blood clots during the course of the disease.
The primary goal of the study was to define and compare the clinical outcomes and resource usage of hospitalised Covid-19 patients. The study also evaluated the effects of anticoagulant therapy on outcomes.
Description and comparison of demographic; visit; hospital; and clinical characteristics between exposure arms, were included as the secondary goals.
According to the findings, patients on a prophylactic dose of the anticoagulants enoxaparin or heparin have shorter hospital stays, reduced expenses and improved clinical outcomes as against those receiving a therapeutic dose, researchers noted.
Furthermore, when the therapeutic arm is categorised by age, laboratory values indicated that younger subjects were as sick as the older patients, without any enhanced outcomes reported.
These data reinforce the American Society of Hematology (ASH) 2021 guidelines conditionally advising the prophylactic dose of anticoagulants for thromboprophylaxis in Covid-19 patients.
In addition, the findings also imply that changes in outcomes by treatment dosage are not associated with the age of the patients.
Meitheal Pharmaceuticals CEO Tom Shea said: “We are proud to partner with Premier to identify Covid-19 treatment options that offer better patient outcomes.
“At Meitheal, we continuously work towards bridging important gaps in healthcare with an affordable and diversified range of generic injectables, and by assessing the effects of anticoagulant treatment on patient outcomes, we can help to improve care for Covid-19 patients.”
US-based company Meitheal Pharmaceuticals delivers generic injectables and has a diversified product range, including antibiotics, anticoagulants, muscle relaxants and chemotherapy drugs among others.
Premier Life Sciences group vice-president Denise Juliano said: “Premier’s Healthcare database will continue to provide life sciences partners like Meitheal the opportunity to use real-world data to conduct evidence-based studies of drugs and clinical outcomes in an effort to improve the overall quality, safety and cost-effectiveness of care.”